Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Natalizumab in multiple sclerosis: proceed with caution?

Doggrell, SA (2006). Natalizumab in multiple sclerosis: proceed with caution?. Expert Opinion on Pharmacotherapy,7(12):1675-1678.

Document type: Journal Article
Citation counts: Scopus Citation Count Cited 2 times in Scopus Article | Citations

Google Scholar Search Google Scholar

Title Natalizumab in multiple sclerosis: proceed with caution?
Author Doggrell, SA
Journal Name Expert Opinion on Pharmacotherapy
Publication Date 2006
Volume Number 7
Issue Number 12
ISSN 1465-6566   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-33747072908
Start Page 1675
End Page 1678
Total Pages 4
Publisher Informa Healthcare
HERDC Category C1 - Journal Article (DEST)
Abstract Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the CNS. In a Phase II clinical trial, natalizumab was shown to reduce the relapses in patients with relapsing MS, without improving the disability score. After 1-year of Phase III clinical trials, natalizumab was approved by the FDA for use in relapsing MS but was withdrawn 3 months later, due to two reported cases of progressive multifocal leukoencephalopathy (PML). The completed clinical trials with natalizumab for relapsing MS have recently been reported. In a trial of 1171 subjects with relapsing MS, natalizumab alone was shown to reduce the relapse rate and lesions, without causing PML. Although natalizumab was also shown to reduce the relapse rates and lesions in patients taking IFN-beta, two cases of PML with natalizumab occurred in these patients. An assessment of patients who had taken natalizumab for 1 - 2 years (similar to 3000), showed the incidence of PML to be 1/1000. A drug that is useful in relapsing MS will be used as along-term therapy in large numbers of patients. For instance, in the 3 months that natalizumab was registered, 5000 patients commenced taking it. In the author's opinion, large numbers of patients should not be allowed to take natalizumab until its safety has been monitored in the long-term use in a clinical trial environment.
Keywords clinical trials
ifn-beta
multiple sclerosis
natalizumab
progressive multifocal leukoencephalopathy
progressive multifocal leukoencephalopathy
controlled trial
DOI http://dx.doi.org/10.1517/14656566.7.12.1675   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 125 Abstract Views  -  Detailed Statistics
Created: Wed, 28 Nov 2007, 14:16:08 CST